申聯生物(688098.SH):擬與科鋭邁德合作開發動物mRNA疫苗及藥物項目
格隆匯4月18日丨申聯生物(688098.SH)公佈,公司與蘇州科鋭邁德生物醫藥科技有限公司(簡稱“科鋭邁德”)簽訂《合作協議》,雙方擬共同設立合資公司推進mRNA平台技術在獸用生物製品領域的相關產品研發、臨牀研究、商業化生產及銷售等業務。公司本次以現金出資,預計現金方式出資不超過1.2億元,其中首期出資3000萬元。
科鋭邁德以其擁有的環狀mRNA平台技術相關專利及專有技術在獸用生物製品領域在中國大陸的獨佔許可使用權出資,無形資產的出資作價根據雙方聘請的專業評估機構出具的評估結果協商確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.